Five-Year Outcomes of Treat and Extend Regimen Using Intravitreal Aflibercept Injection for Treatment-Naive Age-Related Macular Degeneration

Five-Year Outcomes of Treat and Extend Regimen Using Intravitreal Aflibercept Injection for Treatment-Naive Age-Related Macular Degeneration - Five-Year Outcomes of Treat and Extend Regimen Using Intravitreal Aflibercept Injection for Treatment-Naive Age-Related Macular Degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052626

Enrollment

100

Registered

2023-10-31

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients were included in the study if they had been continuously treated with intravitreal aflibercept injections using the TAE regimen for at least 1 years.

Exclusion criteria

Exclusion criteria: Patients who received treatment including anti-VEGF intravitreal injections prior to initiation of aflibercept intravitreal injections or who have diabetic retinopathy, myopic choroidal neovascularization, or other retinal diseases in addition to AMD

Design outcomes

Primary

Measure	Time frame
Data including best-corrected visual acuity (BCVA), intervals of treatments, the presence of exudation, central retinal thickness (CRT), and central choroidal thickness (CCT) were analyzed.	—

Countries

Japan

Contacts

Public ContactHikaru Ota

Nagoya University Hospital Ophthalmology

hkaruu.otaa@gmail.com052-741-2111

Outcome results